Please Wait...

Medical Imaging

8 Essential Imaging Strategies to Revolutionize Your Clinical Study

  • 0
  • 16 Oct

Imaging is utilized in clinical trials across most therapeutic areas and is leveraged to monitor safety, assess efficacy, and provide primary, secondary or exploratory endpoints. The challenge imaging has faced ever since it's been incorporated into clinical trials is that it has succumbed to being "the forgotten one". Many times the preparation and conduct of imaging is an afterthought in clinical trials and for whatever reason is thought to be an easy part of the study design, implementation and execution. Nothing could be further from the truth.

Read More
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices

Congressman Patrick Meehan Visits Bioclinica

  • 0
  • 31 Aug

Bioclinica was honored to host Congressman Patrick Meehan representing the 7th Congressional District in Pennsylvania in a visit to our Audubon, Pennsylvania offices on August 28. Congressman Meehan met with Bioclinica senior leadership, including our CEO Dr. John Hubbard...

Read More

Cardiovascular Imaging: Not Just for Cardiovascular Trials

  • 0
  • 03 Aug

Cardiovascular disease is the leading cause of death globally with approximately 17.3 million deaths annually. Underlying heart disease are numerous conditions such as atherosclerosis, myocardial infarction, ischemic stroke, heart failure, arrhythmias and heart valve issues.

Read More

Bioclinica Medical Imaging 'Raising the Bar'

  • 0
  • 23 Jun

As President of Bioclinica's Medical Imaging & Biomarkers business it is my pleasure to share with you that our team has been recognized by a top biopharma company with the 2017 'Raising the Bar' award for delivering medical imaging excellence in support of multiple global clinical development programs.

Read More

Biomarkers and Personalized Medicine: Essential Tools

  • 0
  • 28 Mar

The use of biomarkers is expanding across all stages in the drug development process, helping bring about new and innovative practices in the treatment of many diseases, including Alzheimer's and cancer. With their ability to revolutionize development of advanced therapeutics, biomarkers have become essential tools.

Read More

Pathway to Quality Cardiovascular Imaging Trials

  • 0
  • 13 Mar

Cardiovascular diseases are the leading cause of death in the world and as such, the cause, prevention and treatment of all cardiovascular disease remains a very active field in the research community. Cardiovascular Imaging is a primary therapeutic service area for Bioclinica, offering comprehensive centralized medical imaging services and support for the majority of all cardiovascular imaging (CVI) modalities leveraged to provide critical endpoint assessments in clinical research.

Read More

Trends in Asia Drug Development Market

  • 0
  • 01 Nov

Innovation and Harmonization on the Rise

As R&D costs continue to hit new heights and domestic participation in clinical trials wane, more and more biopharmaceutical companies are seeking ways to mitigate costs and access new patient populations. Over the past decade, these driving market forces have contributed to a sharp rise in R&D activities, pharmaceutical market size, and the number of clinical trials conducted in Asia.

Read More
Bioclinica on Worldwide Business with Kathy Ireland

Worldwide Business with Kathy Ireland features Bioclinica!

  • 0
  • 06 May

Catch a candid discussion with Bioclinica experts as they discuss clinical trials and ways to simplify the clinical development process in a recent episode of Worldwide Business with Kathy Ireland®!

Each week the Fox Business Network sponsored program explores the real-world insights of corporate executives from around the globe.

Read More

Seeking Clarity in the Audit Approach

  • 0
  • 18 Apr

Many questions still remain several years after the July 2012 ODAC (Oncologic Drug Advisory Committee) Meeting on the "Evaluation of Radiologic Review of Progression-free Survival in Non-Hematologic Malignancies." Further investigation was recommended into the utility of taking an audit approach (central reads of a test sample) to identify potential bias in the local evaluation (LE) of patient data.

Read More
2015 Asia Events

Expanding Opportunities for Drug Development in Asia

  • 0
  • 06 Oct

Over the last decade, R&D activities, pharmaceutical market size, and the number of clinical trials in Asia has grown tremendously.  As a result, Asian biopharmaceutical companies are developing more products for commercialization in the global market, and International drug development service companies have moved many R&D functions and commercial operations to the APAC region.

Read More
Imaging biomarkers, molecular imaging in oncology clinical trials

Leveraging Imaging Biomarkers to Improve Drug Development

  • 0
  • 02 Jun

Clinicians need ways to better predict patient responses

The estimated cost for developing a drug is approaching upwards of $5 Billion dollars with a process spanning well over a decade. Coupled with high failure rates in late phase clinical trials and increased complexities in acquiring and analyzing clinical trial data, traditional approaches based on the premise of "one size fits all" are becoming less cost effective and suboptimal.

Read More

New Approaches for Measuring Muscle Fatty Infiltration

  • 0
  • 17 Apr

Clinical Trial FIT-ness: New Approaches for Measuring Fat

The presence of fatty infiltration in muscles of the lower extremities (thigh and calf) serves as a proxy for impaired muscle function and metabolic status, often seen with musculoskeletal diseases like osteoarthritis (OA), Sarcopenia, Duchenne Muscular Dystrophy, Pompe disease and Polymyositis/Dermatomyositis. Most clinical research for musculoskeletal diseases relies on non-invasive imaging methodologies for assessing changes in inter-muscular adipose tissue (inter-MAT), intra-muscular adipose tissue (intra-MAT) and muscle in the lower extremities.

Read More

Evaluating Cardiotoxicity: The Importance of Strain Imaging

  • 0
  • 27 Feb

Cardiotoxicity stemming from oncology drugs is a common problem facing drug sponsors, clinicians and cancer patients. Drug-induced cardiotoxic effects can be classified based on the mechanism of toxicity into three broad categories: myocardial damage and Left Ventricular (LV) dysfunction, vascular abnormalities and hypertension, and QT prolongation and arrhythmias.

Read More

Escalating Role of Medical Imaging in AD Clinical Trials

  • 0
  • 30 Jan

Alzheimer's disease is one of the most important health challenges facing aging populations worldwide. Disease modifying therapies are desperately needed and many potential treatments are currently being tested in clinical trials. The role and impact of medical imaging in AD trials continues to grow, especially as clinicians and scientists seek to define and treat AD at the earliest stages of disease.

Read More
3 Reasons to Share Data from Unsuccessful Clinical Trials

3 Reasons to Share Data from Unsuccessful Clinical Trials

  • 0
  • 25 Nov

A recent proposal by the U.S. Department of Health and Human Services (HHS) could expand the amount of clinical trial data that drug companies must share with the public. Under the proposal, clinical trial sponsors would be required to report findings for drugs and devices that fail to reach approval.
 

Read More

Pages

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Great advice from our Dir. Cardiovascular Imaging on quality imaging acquisitions & assessments in clin trials. https://t.co/OVH7pZ3SL0
bioclinica (42 minutes ago)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will give a… https://t.co/8ymd2Q9KcJ
bioclinica (52 minutes ago)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will giv… https://t.co/MpxTDV1T1L
bioclinica (54 minutes ago)
RT @bioclinica: Keeping to timelines in #clinicaltrials is key but can be hard to achieve. Join Bioclinica's Justin Hunt a webinar Nov. 2…
bioclinica (57 minutes ago)
RT @Xtalks: Removing Risk from #ClinicalTrial Management System (CTMS) Implementations @bioclinica https://t.co/EfuSVMSL13
bioclinica (7 hours ago)
Our Research Dev. Director Marieke Cajal in a poster presentation at #CNS Summit showed, "How to Scale up Recruitme… https://t.co/ySQpGIjvt9
bioclinica (7 hours ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices